Virax Biolabs Secures ISO Certifications to Propel IVD Development and Clinical Validation in the U.S. Virax Biolabs Group has achieved ISO certifications, enhancing its framework for regulated IVD development, crucial for clinical validation efforts in the U.S.

Virax Biolabs Secures ISO Certifications to Propel IVD Development and Clinical Validation in the U.S. #London #United_Kingdom #ISO_Certification #Virax_Biolabs #Clinical_Validation

Virax Biolabs Group Closes $5 Million Funding Round to Boost Immunology Research Virax Biolabs Group Limited has successfully closed a $5 million private placement to enhance its immunology research, extending operational funding into 2028.

Virax Biolabs Group Closes $5 Million Funding Round to Boost Immunology Research #London #United_Kingdom #biotechnology #Virax_Biolabs #Immunology

Virax Biolabs Group Secures $5 Million in Private Placement Funding Virax Biolabs Group Limited has successfully announced a $5 million private placement, aiming for growth in immunology research and diagnostics.

Virax Biolabs Group Secures $5 Million in Private Placement Funding #London #United_Kingdom #Private_Placement #Virax_Biolabs #Immunology

Virax Biolabs CEO James Foster Shares Key Insights on Progress and Future Goals for 2026 Virax Biolabs' CEO, James Foster, outlines major clinical advancements and strategic objectives ahead for 2026 in a recent letter to shareholders, spotlighting the company's dedication to innovative immunology.

Virax Biolabs CEO James Foster Shares Key Insights on Progress and Future Goals for 2026 #London #United_Kingdom #Virax_Biolabs #James_Foster #Immune_Diagnostics

Virax Biolabs Completes UK Study Recruitment and Receives Positive FDA Feedback on ViraxImmune™ Assay Virax Biolabs Group has completed UK recruitment for its clinical study on the ViraxImmune™ assay, evaluating T cell dysfunction. Positive FDA feedback supports future development.

Virax Biolabs Completes UK Study Recruitment and Receives Positive FDA Feedback on ViraxImmune™ Assay #無し #Virax_Biolabs #T_cell_dysfunction #ViraxImmune

Virax Biolabs Welcomes Dr. Iain Miller to Board to Boost Strategic Growth Virax Biolabs has appointed Dr. Iain Miller as an Independent Director, enhancing their board to advance their commercial strategy and technology.

Virax Biolabs Welcomes Dr. Iain Miller to Board to Boost Strategic Growth #London #United_Kingdom #diagnostics #Virax_Biolabs #Iain_Miller

Virax Biolabs Faces NASDAQ Minimum Bid Price Deficiency Notice Virax Biolabs Group Limited has received a notification from NASDAQ about its failure to meet the minimum bid price. The company now has a set period to regain compliance.

Virax Biolabs Faces NASDAQ Minimum Bid Price Deficiency Notice #NASDAQ #biotechnology #Virax_Biolabs

Virax Biolabs Initiates Clinical Study on T Cell Dysfunction for Post-acute Infections Virax Biolabs has begun enrolling patients for a clinical study investigating T cell dysfunction in post-acute infection syndromes, including long COVID.

Virax Biolabs Initiates Clinical Study on T Cell Dysfunction for Post-acute Infections #London #United_Kingdom #Virax_Biolabs #Long_COVID #T_cell_dysfunction

Virax Biolabs to Showcase Innovations at 19th World Immune Regulation Meeting in Davos Virax Biolabs will present groundbreaking findings on T cell dysfunction at the upcoming World Immune Regulation Meeting in Davos, Switzerland.

Virax Biolabs to Showcase Innovations at 19th World Immune Regulation Meeting in Davos #United_Kingdom #Virax_Biolabs #Davos #T_cell_dysfunction #immune_regulation

Virax Biolabs Advocates for Transparency in Vaccine Efficacy Aligned with U.S. Health Initiatives Virax Biolabs emphasizes its technology's support for U.S. health priorities on vaccine efficacy transparency, fostering informed health decisions.

Virax Biolabs Advocates for Transparency in Vaccine Efficacy Aligned with U.S. Health Initiatives #United_States #New_York #Transparency #Virax_Biolabs #vaccine_efficacy

Virax Biolabs' CEO James Foster Shares Strategic Vision for 2025 with Shareholders Virax Biolabs' CEO James Foster provides shareholders with insights on the company's 2025 strategic goals and achievements in immune diagnostics.

Virax Biolabs' CEO James Foster Shares Strategic Vision for 2025 with Shareholders #London #United_Kingdom #Virax_Biolabs #James_Foster #Immune_Diagnostics

Virax Biolabs Partners with Tebubio to Enhance ImmuneSelect Distribution Across Europe Virax Biolabs Group Limited has partnered with Tebubio to expand their ImmuneSelect product distribution throughout Europe, enhancing accessibility.

Virax Biolabs Partners with Tebubio to Enhance ImmuneSelect Distribution Across Europe #London #United_Kingdom #Virax_Biolabs #ImmuneSelect #Tebubio